SI9400195B - Antagonisti endotelinskih receptorjev - Google Patents

Antagonisti endotelinskih receptorjev Download PDF

Info

Publication number
SI9400195B
SI9400195B SI9400195A SI9400195A SI9400195B SI 9400195 B SI9400195 B SI 9400195B SI 9400195 A SI9400195 A SI 9400195A SI 9400195 A SI9400195 A SI 9400195A SI 9400195 B SI9400195 B SI 9400195B
Authority
SI
Slovenia
Prior art keywords
hydrogen
alkyl
halogen
formula
alkoxy
Prior art date
Application number
SI9400195A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9400195A (en
Inventor
Russell Donovan Cousins
John Duncan Elliott
Maria Amparo Lago
Jack Dale Leber
Catherine Elisabeth Peishoff
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of SI9400195A publication Critical patent/SI9400195A/sl
Publication of SI9400195B publication Critical patent/SI9400195B/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30Unsaturated compounds
    • C07C62/34Unsaturated compounds containing ether groups, groups, groups, or groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9400195A 1993-04-27 1994-04-26 Antagonisti endotelinskih receptorjev SI9400195B (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6681893A 1993-04-27 1993-04-27

Publications (2)

Publication Number Publication Date
SI9400195A SI9400195A (en) 1994-12-31
SI9400195B true SI9400195B (sl) 2003-10-31

Family

ID=22071916

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9400195A SI9400195B (sl) 1993-04-27 1994-04-26 Antagonisti endotelinskih receptorjev

Country Status (28)

Country Link
EP (1) EP0699069B9 (cg-RX-API-DMAC7.html)
JP (1) JP3346571B2 (cg-RX-API-DMAC7.html)
KR (1) KR100331667B1 (cg-RX-API-DMAC7.html)
CN (1) CN1129428C (cg-RX-API-DMAC7.html)
AP (1) AP573A (cg-RX-API-DMAC7.html)
AT (1) ATE213156T1 (cg-RX-API-DMAC7.html)
AU (1) AU682038B2 (cg-RX-API-DMAC7.html)
BR (1) BR9406572A (cg-RX-API-DMAC7.html)
CA (1) CA2160914A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ291189B6 (cg-RX-API-DMAC7.html)
DE (1) DE69429861T2 (cg-RX-API-DMAC7.html)
DK (1) DK0699069T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ1773A1 (cg-RX-API-DMAC7.html)
ES (1) ES2172535T3 (cg-RX-API-DMAC7.html)
FI (1) FI955103L (cg-RX-API-DMAC7.html)
HU (2) HUT73763A (cg-RX-API-DMAC7.html)
IL (1) IL109443A0 (cg-RX-API-DMAC7.html)
MA (1) MA23172A1 (cg-RX-API-DMAC7.html)
NO (1) NO313754B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ266314A (cg-RX-API-DMAC7.html)
PL (1) PL175392B1 (cg-RX-API-DMAC7.html)
PT (1) PT699069E (cg-RX-API-DMAC7.html)
RU (1) RU2130920C1 (cg-RX-API-DMAC7.html)
SG (1) SG49667A1 (cg-RX-API-DMAC7.html)
SI (1) SI9400195B (cg-RX-API-DMAC7.html)
SK (1) SK130595A3 (cg-RX-API-DMAC7.html)
TW (1) TW330204B (cg-RX-API-DMAC7.html)
WO (1) WO1994025013A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033748A1 (en) * 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
US5736564A (en) * 1994-06-20 1998-04-07 Smithkline Beecham Corporation Endothelin receptor antagonists
JPH10512855A (ja) * 1994-12-23 1998-12-08 スミスクライン・ビーチャム・コーポレイション 化合物および方法
US6080862A (en) * 1995-11-08 2000-06-27 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
AU7677496A (en) * 1995-11-08 1997-05-29 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
US6162932A (en) * 1995-11-08 2000-12-19 Smithkline Beecham Corporation Stereoselective synthesis of endothelin receptor antagonists
ZA969363B (en) * 1995-11-08 1997-11-18 Smithkline Beecham Corp An improved process for preparing aromatic ring-fused cyclopentane derivatives.
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
JP3345891B2 (ja) 1996-04-04 2002-11-18 萬有製薬株式会社 エンドセリン拮抗薬を含有することを特徴とする心不全治療剤
US5932553A (en) 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
JP3076066B2 (ja) 1996-08-27 2000-08-14 塩野義製薬株式会社 クロメン−3−カルボン酸誘導体
US5929106A (en) * 1997-10-27 1999-07-27 Smithkline Beecham Corporation Endothelin receptor antagonists
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
ATE244214T1 (de) * 1998-04-09 2003-07-15 Merck & Co Inc Phosphat-vermittelte cyclisierung
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
AU2005224014B9 (en) 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
US7423176B2 (en) 2004-04-13 2008-09-09 Cephalon, Inc. Bicyclic aromatic sulfinyl derivatives
MX2007007482A (es) 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos como antagonistas de 5-ht.
US20100040666A1 (en) * 2005-06-24 2010-02-18 Hiroshi Azuma Method for Control of Drug Elution Rate and Composition for Coating of Drug-Eluting Stent
WO2007019308A2 (en) 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737455A (en) * 1971-01-21 1973-06-05 Merck & Co Inc Substituted 1-(loweralkyl-sulfinylbenzylidene)-3-indenyloxyacetic acid and esters thereof
DE69232072T2 (de) * 1991-11-05 2002-06-20 Smithkline Beecham Corp., Philadelphia Endothelin-rezeptor-antagonisten

Also Published As

Publication number Publication date
FI955103A0 (fi) 1995-10-26
EP0699069A4 (cg-RX-API-DMAC7.html) 1996-04-03
SI9400195A (en) 1994-12-31
NO954291L (no) 1995-12-21
IL109443A0 (en) 1994-07-31
CN1129428C (zh) 2003-12-03
EP0699069B1 (en) 2002-02-13
AP9400636A0 (en) 1994-04-30
DE69429861D1 (de) 2002-03-21
PL311272A1 (en) 1996-02-05
TW330204B (en) 1998-04-21
NZ266314A (en) 1998-10-28
NO954291D0 (no) 1995-10-26
RU2130920C1 (ru) 1999-05-27
FI955103A7 (fi) 1995-10-26
AP573A (en) 1997-01-30
DE69429861T2 (de) 2002-09-19
SK130595A3 (en) 1996-06-05
EP0699069B9 (en) 2003-10-22
BR9406572A (pt) 1996-01-30
KR100331667B1 (ko) 2002-11-08
ES2172535T3 (es) 2002-10-01
WO1994025013A1 (en) 1994-11-10
HUT73763A (en) 1996-09-30
AU682038B2 (en) 1997-09-18
CN1124923A (zh) 1996-06-19
NO313754B1 (no) 2002-11-25
HK1012252A1 (en) 1999-07-30
AU6775094A (en) 1994-11-21
EP0699069A1 (en) 1996-03-06
CZ291189B6 (cs) 2003-01-15
PT699069E (pt) 2002-07-31
ATE213156T1 (de) 2002-02-15
DK0699069T3 (da) 2002-05-27
SG49667A1 (en) 1998-06-15
JPH08510211A (ja) 1996-10-29
DZ1773A1 (fr) 2002-02-17
FI955103L (fi) 1995-10-26
MA23172A1 (fr) 1994-12-31
CA2160914A1 (en) 1994-11-10
JP3346571B2 (ja) 2002-11-18
CZ283595A3 (en) 1996-03-13
HU9503067D0 (en) 1995-12-28
HU9501931D0 (en) 1995-09-28
PL175392B1 (pl) 1998-12-31

Similar Documents

Publication Publication Date Title
SI9400195B (sl) Antagonisti endotelinskih receptorjev
SI9200297B (sl) Antagonisti endotelinskih receptorjev
RU95122388A (ru) Антагонисты эндотелинового рецептора
SE8008533L (sv) Antihypertensiva medel
JP2018524339A5 (cg-RX-API-DMAC7.html)
FI4017494T3 (fi) Vmat2-estäjä valbenatsiini käytettäväksi menetelmässä neurologisen tai psykiatrisen häiriön hoitamiseksi potilailla, joilla on vaikea munuaisen vajaatoiminta
RU96112148A (ru) Антагонисты рецепторов эндотелина
GR3023708T3 (en) N-acyl-N-heterocyclyl- or naphthyl-alkyl amino acids as angiotensin II antagonists
RU2003110577A (ru) Гетероциклические соединения, связывающиеся с хемокиновыми рецепторами
AU661299B2 (en) New thalidomide derivatives, method of manufacture and use thereof in medicaments
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
RU2012124266A (ru) Хелаты марганца и их применение в качестве контрастных агентов в магнитно-резонансной визуализации (mpb)
KR920021541A (ko) 벤조푸란 유도체
ATE301117T1 (de) Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
RU2600986C2 (ru) Органические аминные соли азилсартана, способ их получения и применение
JP2023523953A (ja) 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物
CN111971038A (zh) 用于双靶向治疗神经内分泌瘤的组合物和方法
IL113137A (en) Carboxylic acid derivatives for use as drugs
BR9917205A (pt) Antagonistas de retinóides e seu uso
EP2006287B1 (en) Compound with antimalarial activity and antimalarial drug containing the same as active ingredient
ES2182975T3 (es) Nueva quimica heterociclica.
TW496737B (en) Improving the tolerability of pharmaceutically active β-amino acids
JP2014051442A (ja) 前立腺がんを診断可能な核医学イメージングプローブ
RU2004121783A (ru) Пролекарства на основе d-пролина
HRP20100301T1 (hr) Ciklopeptidni derivati sa anti-integrinskom aktivnošću

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20100122